Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 3.
doi: 10.1007/s12185-025-04152-4. Online ahead of print.

Venetoclax-based combination regimens for therapy-related myeloid neoplasms

Tongtong Zhang #  1   2 , Yan Yu #  1   2 , Yanglan Fang  1   2 , Jinyan Xiao  1   2 , Hong Liu  1   2 , Haixia Zhou  3   4 , Mingzhu Xu  5   6
Affiliations

Venetoclax-based combination regimens for therapy-related myeloid neoplasms

Tongtong Zhang et al. Int J Hematol. .

Abstract

Therapy-related myeloid neoplasms (t-MN) are an aggressive and heterogeneous group of myeloid disorders with no established guidelines for frontline treatment. This retrospective study of 53 consecutive t-MN patients at our institution evaluated the influence of clinical features, treatment approaches, and prognostic indicators on clinical outcomes of t-MN. The 1-year, 3-year, and 5-year overall survival (OS) rates were 61.0%, 50.0%, and 36.0%, respectively. Multivariate analysis revealed that age ≥ 60 (p = 0.009), TP53 (p = 0.040) and RAS mutations (p = 0.018) were associated with inferior OS. After induction therapy, patients who received a venetoclax-based regimen (venetoclax group) had an overall response rate (ORR) of 96.2%, compared with 63.6% in the chemotherapy group (p = 0.007). The venetoclax group tended to have better OS and DFS than the chemotherapy group (p = 0.052 and p = 0.078). Importantly, ORR rates and OS were higher in some subgroups of the venetoclax group, especially in patients over 60 years old and patients with intermediate/adverse risk. This study demonstrates the feasibility of venetoclax-based combination regimens for the treatment of t-MN and may influence decision-making for frontline therapy.

Keywords: Chemotherapy; Clinical outcome; Therapy-related myeloid neoplasms; Venetoclax-based regimens.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no conflicts of interest. Ethical approval: This study was approved by the Committee for the Ethical Review of Research at The First Affiliated Hospital of Soochow University and conducted in accordance with institutional guidelines and the Declaration of Helsinki.

References

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. - DOI - PubMed
    1. Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410–25. - DOI - PubMed
    1. Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208–14. - DOI - PubMed
    1. Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77. - DOI - PubMed
    1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33(31):3641–9. - DOI - PubMed

LinkOut - more resources